催化剂制药公司董事出售了522万美元的股票-动脉网

Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock

benzinga 等信源发布 2025-06-11 11:01



可切换为仅中文







Revealing a significant insider sell on June 10,

揭示了6月10日的一笔重大内部抛售，

Patrick J McEnany

帕特里克·J·麦克埃纳尼

, Director at

，导演 tại

Catalyst Pharmaceuticals

催化剂制药公司

CPRX

, as per the latest SEC filing.

，根据最新的SEC文件。

What Happened:

发生了什么：

McEnany opted to sell 200,000 shares of

麦克纳尼选择出售 200,000 股

Catalyst Pharmaceuticals

催化剂制药公司

, according to a Form 4 filing with the

根据Form 4文件的申报，

U.S. Securities and Exchange Commission

美国证券交易委员会

on Tuesday. The transaction's total worth stands at $5,217,338.

星期二。该交易的总价值为5,217,338美元。

As of Wednesday morning,

截至周三早上，

Catalyst Pharmaceuticals

催化剂制药公司

shares are up by 0.96%, currently priced at $26.56.

股价上涨了 0.96%，目前价格为 26.56 美元。

Discovering Catalyst Pharmaceuticals: A Closer Look

发现催化剂制药公司：更深入的观察

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone)..

Catalyst制药公司是一家生物制药公司。该公司专注于开发和商业化，为患有罕见、严重、慢性神经肌肉和神经疾病的患者开发疗法。该公司提供三种药物产品，分别为FIRDAPSE（阿米法普里定）、FYCOMPA（吡仑帕奈）和AGAMREE（瓦莫罗隆）。

Catalyst Pharmaceuticals: A Financial Overview

催化剂制药公司：财务概况

Revenue Growth:

收入增长：

Catalyst Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of

Catalyst Pharmaceuticals 在短短三个月内的表现显著。截至 2025 年 3 月 31 日，该公司实现了令人印象深刻的收入增长率。

43.56%

. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

这标志着公司收入的大幅增长。然而，与行业同行相比，该公司的增长率低于医疗保健行业的平均增长率，处于落后地位。

Evaluating Earnings Performance:

评估盈利表现：

Gross Margin:

毛利率：

The company issues a cost efficiency warning with a low gross margin of

公司因毛利率低而发布成本效率警告

87.33%

, indicating potential difficulties in maintaining profitability compared to its peers.

，表明与同行相比，维持盈利能力可能存在困难。

Earnings per Share (EPS):

每股收益 (EPS):

With an EPS below industry norms, Catalyst Pharmaceuticals exhibits below-average bottom-line performance with a current EPS of

由于每股收益低于行业标准，Catalyst Pharmaceuticals 的当前每股收益表现出低于平均水平的底线业绩

0.47

。

Debt Management:

债务管理：

Catalyst Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of

Catalyst Pharmaceuticals的债务股本比低于行业标准，表明其财务结构稳健，比率是

0.0

。

Evaluating Valuation:

评估估值：

Price to Earnings (P/E) Ratio:

市盈率 (P/E)：

The Price to Earnings ratio of

市盈率

16.76

is lower than the industry average, indicating potential undervaluation for the stock.

低于行业平均水平，表明该股票可能存在低估。

Price to Sales (P/S) Ratio:

市销率（P/S）：

The current P/S ratio of

当前的市销率

6.19

is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.

低于行业标准，表明可能存在低估，为考虑销售业绩的投资者提供了投资机会。

EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization):

EV/EBITDA分析（企业价值与其息税折旧摊销前利润的比率）：

The company's EV/EBITDA ratio of

该公司的EV/EBITDA比率

9.78

trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.

trails industry averages，表明市场估值可能存在潜在差异，这对投资者来说可能是有利的。

Market Capitalization:

市值：

With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

由于市值受限，该公司位于行业平均水平以下，这反映出其相对于同行规模较小。

Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.

现在通过查尔斯·施瓦布这家值得信赖且全面的投资公司在线免费交易股票。

Why Pay Attention to Insider Transactions

为什么要关注内幕交易

In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.

在投资决策的复杂环境中，投资者应将内部人士交易作为综合分析的一部分，并考虑各种因素。

Considering the legal perspective, an 'insider' is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction..

从法律角度来看，根据1934年《证券交易法》第12条，“内幕人士”被定义为任何公司高管、董事或持有超过公司股本证券10%的受益所有人，包括首席高管和大型对冲基金。这些内幕人士必须通过表格4披露其交易，并需在交易后两个工作日内提交。

Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.

指向乐观主义，一位公司内部人士的新购买信号表明他们对股票上涨持积极预期。

Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.

然而，内部人士抛售并不一定代表看跌观点，可能受到各种因素的影响。

Unlocking the Meaning of Transaction Codes

解锁交易代码的含义

When it comes to transactions,

当谈到交易时，

investors

投资者

tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A

倾向于关注那些在公开市场上的交易，详细信息见表格I的Form 4文件。一个

in Box 3 denotes a purchase, while

方框3中的符号表示购买，而

indicates a sale. Transaction code

表示出售。交易代码

signals the conversion of an option, and transaction code

表示选项的转换，以及交易代码

denotes a grant, award, or other acquisition of securities from the company.

表示从公司获得的赠款、奖励或其他证券收购。

Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.

查看 Catalyst Pharmaceuticals 内部交易的完整列表。

Insider Buying Alert: Profit from C-Suite Moves

内部买入警报：从高管动向中获利

Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now.

Benzinga Edge实时揭示每一笔内部人士交易。不要错过下一次由内部人士信心推动的重大股票波动。立即解锁这一终极情绪指标。

Click here for access

点击此处访问

。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自动化内容引擎生成，并由编辑审核。

CPRX

心肺复苏术

Catalyst Pharmaceuticals Inc

催化剂制药公司

$26.04

26.04美元